Jeff Mason is a White House Correspondent for Reuters and the 2016-2017 president of the White House Correspondents’ Association. He was the lead Reuters correspondent for President Barack Obama's 2012 campaign and interviewed the president at the White House in 2015. Jeff has been based in Washington since 2008, when he covered the historic race between Obama, Hillary Clinton and John McCain. Jeff started his career in Frankfurt, Germany, where he covered the airline industry before moving to Brussels, Belgium, where he covered the European Union. He is a Colorado native, proud graduate of Northwestern University and former Fulbright scholar.
Twitter handle: @jeffmason1
Loxo Oncology on Tuesday signed a collaboration agreement for its promising cancer drugs with Germany's Bayer AG that could be worth up to $1.55 billion to the tiny U.S. company, but its shares fell 11 percent as the deal appeared to end near-term likelihood of a takeover.
Sage Therapeutics Inc's shares surged to a record on Thursday after its postpartum depression drug succeeded in two late-stage studies, paving the way for it to bring to market the first FDA-approved treatment for the disorder.
AmerisourceBergen Corp said it expects stubbornly low generic drug prices, which have plagued drugmakers and wholesalers, to not deteriorate further next year, and brushed off concerns about Amazon's possible entry into the industry.
Allergan Plc on Wednesday reassured shareholders that it would return to earnings growth in 2019 after losing a major patent ruling last month on its second-most important drug, dry-eye treatment Restasis. | Video
Endo International Plc on Monday gave a glimpse of a quarter that could help ease investor concerns when it announced preliminary earnings well above market estimates, sending the generic-drug maker's shares up as much as 18 percent.
AbbVie Inc forecast its flagship drug Humira to bring $21 billion in sales by 2020, about $3 billion higher than its expectation two years ago, driving the U.S. drugmaker's shares up 4 percent on Friday.
U.S. medical device maker Boston Scientific Corp's shares fell 5 percent on Thursday after disappointing sales in its pacemaker business, even as the company reported better-than-expected revenue overall in the third quarter.
Eli Lilly and Co said on Tuesday it is considering the sale of its Elanco animal health business and expressed optimism that its rejected rheumatoid arthritis drug would pass muster with U.S. regulators when it resubmits its application.
NeuroPace Inc said on Tuesday it raised $74 million in equity funding as the medical device maker looks to rapidly expand commercialization of its device to treat epileptic seizures.
DBV Technologies SA said on Friday its peanut allergy treatment did not meet the main goal in a highly anticipated late-stage study, sending its U.S.-listed shares sharply down.
- Gold: PRECIOUS-Gold at one-month top on weak dollar, uncertainty over Trump tax bill
- Oil Report: Governments keep global climate deal on track despite U.S. pullout
- British Pound Report: Sterling trims early gains as Brexit nervousness sets in
- US Dollar Report: FOREX-Dollar weak on worries over U.S. tax reform outlook, Mueller probe